PPD, Inc. has signed a new three-year agreement with Pfizer to provide drug development services to advance Pfizer’s portfolio. Pfizer has the right to extend the term for additional two-year periods. Financial details were not disclosed. The agreement builds on the companies’ existing relationship, in which PPD provides wide-ranging services in global clinical development and lab services to support Pfizer’s drug development initiatives across multiple therapeutic areas. “United in purp...